Fresenius Medical Care (FMEA) Q2 2026 Earnings Report

The call balanced meaningful operational and financial progress against notable execution and external headwinds. Highlights include strong operating income growth (+23%), margin expansion (+180 bps), EUR 67 million of sustainable FME25+ savings, improved cash generation (+11% operating cash flow), a successful 5008X rollout (227 clinics, >600k treatments) and a profitable turnaround in value-based care (EUR 18m operating income). Lowlights include a U.S. referral/capture execution gap driving a 0.9% decline in U.S. same‑market treatments and an expectation that U.S. volumes will remain around the Q2 level for 2026, regulatory and inflationary pressures in China and Care Enablement (EUR ~20m Q2 headwind), a EUR 103m special-item charge (TAVNEOS impairment), and TDAPA timing creating an H2 earnings headwind (net ~EUR 50m for the year). Overall, the positives around profitability, cash flow, capital returns and product rollout outweigh the near-term volume and regulatory challenges, though execution on U.S. referrals and China strategy will be key to sustaining momentum.

Management reiterated a broadly flat full‑year 2026 revenue outlook and said operating income should remain at a consistently elevated level (up/down mid‑single‑digit % range), confirming the full‑year guidance; they expect U.S. same‑market treatment growth for 2026 to be around the Q2 level (Q2 U.S. -0.9%, international +0.8%) and value‑based care to perform around breakeven for the year. They trimmed the expected full‑year TDAPA headwind to ~€50m (from ~€100m previously), noting Q2 showed ~€80m year‑over‑year TDAPA benefit while binders were ~€70m positive in H1 but are expected to become ~€120m negative in H2, netting the ~€50m FY effect; portfolio optimization is assumed to shave ~30 bps off FY revenue (50 bps in Q2). Operationally, FME25+ delivered ~€67m of sustainable quarterly savings (with ~€42m one‑time FME25+ costs and total special items of ~‑€103m in Q2), group operating income grew 23% in Q2 with ~180 bps margin expansion, organic group revenue was +5% (cc +4%), operating cash flow rose 11% and free cash flow was €625m, total net debt + lease liabilities up 6% YoY, net leverage ~2.6x (target corridor 2.5–3x), and the company completed a €1bn buyback and launched a second €1bn program (first tranche up to €600m, €94m repurchased so far: 2.5m shares ≈0.9% of share capital).